Resources Repository
-
GuidelinesPublication 2013Guide to the Methods of Technology Appraisal 2013
The National Institute for Health and Care Excellence (NICE, or the Institute) provides guidance to …
The National Institute for Health and Care Excellence (NICE, or the Institute) provides guidance to the NHS in England on the clinical and cost effectiveness of selected new and established technologies. The Institute undertakes appraisals of health technologies at the request of the Department of Health. Guidance produced by the Institute on health technologies is also applied selectively in Northern Ireland, Scotland and Wales. The purpose of this document is to provide an overview of…
Priority Setting/Ethics | Technology Assessment | Europe | Cost-Effectiveness Analysis | Health Systems | Policy/Regulation | Government/Law | Health/Medicine -
ArticlePublication 2023Evolving Nature of Health Technology Assessment: A Critical Appraisal of NICE's New Methods Manual
The National Institute for Health and Care Excellence (NICE) updated its Health Technology Evaluation manual …
The National Institute for Health and Care Excellence (NICE) updated its Health Technology Evaluation manual in 2022, merging processes from all 4 Health Technology Evaluation programs into a single document. Key changes include introducing a new disease severity modifier while maintaining existing methods on health inequality, discounting, unrelated healthcare costs, and value of information. Changes were categorized by importance, with most being modest updates or clarifications aligning with existing principles. The methods involved a 2-stage…
Technology Assessment | Europe | Health/Medicine -
ArticlePublication 2023Top and Bottom Longevity of Nations
Similar to the study of the distribution of income within countries, population-level health disparities can …
Similar to the study of the distribution of income within countries, population-level health disparities can be examined by analyzing the distribution of age at death. This article exposes a characterization of the age-at-death distribution across populations with a focus on the lower and upper tails of the distribution. These metrics, specifically the gap measures in age and share across the 10th and 90th percentiles of the distribution, enable a systematic comparison of national performances, which…
Priority Setting/Ethics | Europe | North America -
ArticlePublication 2022Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face …
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face of uncertainty. This study aimed to quantify consequences of approving therapies or pursuing further research. The authors used a cohort state-transition model for hospitalized patients with COVID-19 to estimate quality-adjusted life-years (QALYs) and costs associated with multiple drug regimens and usual care. For each they assessed immediate approval, use only in research, emergency use authorization or reject. They conducted cost-effectiveness…
Benefit-Cost Analysis | Europe | Value of Information | State-Transition | Infectious Diseases | Policy/Regulation | Economics/Finance | North America -
ArticlePublication 2022Comparing Health Gains, Costs & Cost-Effectiveness of Interventions in Australia & New Zealand
This paper synthesizes the health gains, costs, and cost-effectiveness of health interventions in Australia and New …
This paper synthesizes the health gains, costs, and cost-effectiveness of health interventions in Australia and New Zealand (NZ) from studies conducted with comparable methods, and reports results in the form of an online interactive league table. Studies from the Australia Cost-Effectiveness research and NZ Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programmes and studies were included which reported health-adjusted life years (HALYs) and net health system costs and/or incremental cost-effectiveness ratios, used a time horizon of…
Priority Setting/Ethics | Oceania | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Mental Health | Health Systems | Health/Medicine | Asia & Pacific -
ArticlePublication 2016Country-Level Cost-Effectiveness Thresholds
This article estimates the cost-effectiveness thresholds (CETs) for health interventions in several low and middle-income …
This article estimates the cost-effectiveness thresholds (CETs) for health interventions in several low and middle-income countries (LMICs), based on opportunity costs. When there are constraints on a health care system’s budget or ability to increase expenditures, additional costs imposed by interventions have an “opportunity cost” in terms of the health foregone because other interventions cannot be provided. The authors argue that cost-effectiveness thresholds should reflect health opportunity cost and aim to calculate these in four…
Priority Setting/Ethics | Europe | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
GuidelinesPublication 2016Estimating Health-State Utility for Economic Models: ISPOR Task Force Report
Cost-utility models are increasingly used in many countries to establish whether the cost of a …
Cost-utility models are increasingly used in many countries to establish whether the cost of a new intervention can be justified in terms of health benefits. Health-state utility (HSU) estimates (the preference for a given state of health on a cardinal scale where 0 represents dead and 1 represents full health) are typically among the most important and uncertain data inputs in cost-utility models. Clinical trials represent an important opportunity for the collection of health-utility data.…
Technology Assessment | Europe | Preferences/Values | Health Outcomes | Mathematical Models | Cost-Effectiveness Analysis | Health Systems | Health/Medicine | Science/Technology | North America -
ArticlePublication 2016Estimating the Cost-Effectiveness of Implementation: Is Sufficient Evidence Available?
Timely implementation of recommended interventions can provide health benefits to patients and cost savings to …
Timely implementation of recommended interventions can provide health benefits to patients and cost savings to the health service provider. Effective approaches to increase the implementation of guidance are needed. Since investment in activities that improve implementation competes for funding against other health generating interventions, it should be assessed in term of its costs and benefits. In 2010, the National Institute for Health and Care Excellence released a clinical guideline recommending natriuretic peptide (NP) testing in…
Operations Research | Europe | Health Outcomes | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Clinical Care | Economics/Finance | Health/Medicine -
GuidelinesPublication 2016Methods for Health Economic Evaluation of Vaccines
This article describes the development of a consensus for health economic evaluations of vaccines to …
This article describes the development of a consensus for health economic evaluations of vaccines to support the development of national guidelines in Europe. While guidelines advocating more standardization of health economic evaluations exist, this article aims to address several immunization-specific aspects (e.g. indirect effects or discounting approach) which are still a subject of debate. The systematic literature review search was informed by expert opinion. 2,838 articles were returned from the search and 26 were finally…
Dynamic Transmission | Europe | Costing Methods | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Health/Medicine